Drug Design, Development and Therapy

Open Access Full Text Article

RETRACTED ARTICLE: Coffee and caffeine potentiate the antiamyloidogenic activity of melatonin via inhibition of A β oligomerization and modulation of the Tau-mediated pathway in N2a/APP cells

Li-Fang Zhang^{1,2} Zhi-Wei Zhou² Zhen-Hai Wang¹ Yan-Hui Du¹ Zhi-Xu He³ Chuanhai Cao² Shu-Feng Zhou^{2,3}

¹Department of Neurology, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, People's Republic of China; ²Department of Pharmaceutical Science, College of Pharmacy, University of South Florida, Tampa, FL, USA; ³Guizhou Provincial Key Laboratory for Regenerative Medici Stem Cell and Tissue Engineering Research Center and Sino-US Laboratory for Medical Sciences, Guiyang Medical Universid Guiyang, ic of Chi Guizhou, People's Rep



Correspondence: Shu-Feng Zhou; Chuanhai Cao Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, 12901 Bruce B Downs Blvd, MDC 30, Tampa, FL 33612, USA Tel +1 813 974 6276; +1 813 396 0742 Fax +1 813 905 9885 Email szhou@health.usf.edu; ccao@health.usf.edu

of Alzh er's dise (AD), which has become Abstract: There is an increasing prevalen ng mechanis. a public health issue. However, the und for the pathogenesis of AD are not fully understood, and the current the apeutic logs cannot produce acceptable efficacy in AD patients. Previous animal studies have shown the coffee (Coff), caffeine (Caff), and melaects on AD. Disturbed circadian rhythms are observed in AD, tonin (Mel) have beneficial and chronotherapy has shown promising fects on AD. In this study, we examined whether a combination of Coff or C f plus Mel p duced a synergistic/additive effect on amyloid- β Neuro-2a (2a)/approvid precursor protein (APP) cells and the possible $(A\beta)$ generation were treated with Coff or Caff, with or without combined Mel, with mechanisms invo ea. ological temperature in the second seco three different chr wed by Mel for 12 hours in the night. For regimen 2, cells were treated 12 hou e day, i Coff or lff plus el for 24 hours, from 7 am to 7 am the next day. In regimen 3, cells were wit ted with Cat plus Mel with regimen 1 or 2 for 5 consecutive days. The extracellular and Aβ oligomer levels were determined using enzyme-linked immunosorbent assay Αβ4 (ELISA) its. The expression and/or phosphorylation levels of glycogen synthase kinase 3β (GSK3 β), $R_{1/2}$, PI3K, Akt, Tau, Wnt3 α , β -catenin, and Nrf2 were detected by Western blot ay. The results showed that regimen 1 produced an additive antiamyloidogenic effect with sign, cantly reduced extracellular levels of A β 40/42 and A β 42 oligomers. Regimen 2 did not result in remarkable effects, and regimen 3 showed a less antiamyloidogenic effect compared to regimen 1. Coff or Caff, plus Mel reduced oxidative stress in N2a/APP cells via the Nrf2 pathway. Coff or Caff, plus Mel inhibited GSK3β, Akt, PI3K p55, and Tau phosphorylation but enhanced PI3K p85 and Erk1/2 phosphorylation in N2a/APP cells. Coff or Caff, plus Mel downregulated Wnt3 α expression but upregulated β -catenin. However, Coff or Caff plus Mel did not significantly alter the production of T helper cell (Th)1-related interleukin (IL)-12 and interferon (IFN)- γ and Th2-related IL-4 and IL-10 in N2a/APP cells. The autophagy of cells was not affected by the combinations. Taken together, combination of Caff or Coff, before treatment with Mel elicits an additive antiamyloidogenic effects in N2a/APP cells, probably through inhibition of Aβ oligomerization and modulation of the Akt/GSK3β/Tau signaling pathway. **Keywords:** Alzheimer's disease, A β oligomer, coffee, caffeine, melatonin, Tau, Nrf2, chronotherapy, Akt

Introduction

Alzheimer's disease (AD) is a primary type of dementia (60%–80%) that is characterized by progressive loss of memory and cognition, brain atrophy, and accumulation of

submit your manuscript | www.dovepress.com Dovepress http://dx.doi.org/10.2147/DDDT.S71106 Drug Design, Development and Therapy 2015:9 241-272

© 2015 Zhang et al. This work is published by Dove Medical Press Limited, and licensed under Greative Commons Attribution — Non Commercial (unported, v3.0) permission from Dove Medical Press Limited, provided the work is properly attributed. Premissions beyond the scope of the License are administered by Dove Medical Press Limited, provided the work is properly attributed. Premissions beyond the scope of the License are administered by Dove Medical Press Limited, provided the work is properly attributed. Premissions beyond the scope of the License are administered by Dove Medical Press Limited, Dove Medical Press Limited, Dove Medical Press Limited, Information on how to request permission may be found at: http://www.dovepress.com/permissions.pp

amyloid plaques and neurofibrillary tangles in the cortex, ultimately leading to complete debilitation and death.^{1,2} Typical clinical symptoms of AD include progressive short-term memory loss, impaired linguistic function, emotional dysfunction, impaired cognition, and dementia. AD can be further subdivided into early-onset (<65 years old, familial) and late-onset (>65 years old, sporadic) groups. Patients with either sporadic or familial AD share common clinical and neuropathological features.^{3,4} The Delphi study estimated that there were 24.3 million people with dementia in the world in 2001 and predicted that this would increase to 42.3 million in 2020 and 81.1 million by 2040.5 The countries or regions with the largest number of affected individuals are the People's Republic of China and the developing Western Pacific, Western Europe, and the USA. There were about 25 million people with AD in 2010, and now nearly 36 million people have AD or a related dementia, worldwide.^{4,6} It is estimated that the number of AD patients will double every 5 years, and the number is expected to be 65.7 million in 2030 and 115.4 million worldwide in 2050 if we cannot find a cure. A recent meta-analysis based on 89 published reports has estimated that the number of people with AD increased from 1.9 million in 1990 to 5.7 million in 2010 in the People's Republic of China.⁷ In the USA, an estimat 5.2 million Americans have AD in 2014 (ie, one in nin Americans over 65 has AD) and ~500,000 people tie from ing ca AD each year, which makes AD the sixth lea e of .11: death.^{6,8,9} By 2050, it is expected that more 13.8 Americans will have AD. AD representer major inc health gives rise concern, and its increasing prevale heavy burden to family and society.^{1,6} For ample, the direct costs to American society charing for the with AD will total an estimated \$214 Illion, including \$1.50 billion in costs to Medicare (\$1 N illion and Medicaid (\$37 billion) in 2014.6 The global cost of AD and comentia is estimated to be \$605 bill on, wh Int to 1.0% of the entire h is eq world's gree dome a moduct.¹²

The etiolog, a AD is not fully deciphered, and its pathogenesis is complice of. The most important risk factor for AD is age, and other AD risk factors include hypertension, stroke, heart diseases, depression, arthritis, type II diabetes, estrogen supplements, and smoking.^{1,2} There is a line of evidence that amyloid- β (A β) and the Tau protein play a key role in the development and progression of AD.^{1,13–17} A β peptides are proteolytic fragments of the transmembrane amyloid precursor protein (APP), whereas Tau is a brain-specific, axon-enriched microtubule-associated protein. APP is primarily processed by the aspartyl proteases β - and γ -secretase, and the β -secretase

1 (known as β -site APP cleaving enzyme 1 [BACE1], also named memapsin and Asp2) that is predominantly expressed in the brain as an integral membrane protein, with its carboxyl terminal end associated with the membrane in endosomes.¹⁸⁻²⁰ In the nonamyloid genic pathway, the α -secretase (ie, a disintegrin and metalloproteinase domain protein 10 [ADAM10]) prevents formation of toxic A β peptides from APP and alternatively catalyzes the formation of neuroprotective and neurotrophic soluble fragments (APPs-a) and membranebound fragment, C83.¹⁸⁻²⁰ C83 is subsequently cleaved by the γ -secretase complex to yield the 3 kProgramment, P3, and dation $\delta \beta$ leads to an APP intracellular domain. Accu plaque development, and hyperphothorylation a aggregation of Tau protein, resulting the formation of tagles.^{1,11–15} The behavioral symptom of AD correlate via the aggregation of A β and phospholon tion well of Tau.⁴⁷ Moreover, A β has been consider a to be supstreat regulator of Tau in AD pathogene at triggers nversion of Tau from a On the other hand, it was shown that normal to a toxic stat Tau entropy $A\beta$ toxicity is a feedback loop.^{1,11–15} Given the I role of AB and Tau in the pathogenesis of AD, both criti Aβ nd Tau-associated pathways are the central targets for the deelopment of new therapies aimed to ameliorate the development and progression of AD.^{15,21–23} To date, there is AD. Currently available therapeutic drugs for AD no erapy approved by the US Food and Drug Administration nclude donepezil, galantamine, memantine, rivastigmine, and crine. Only memantine is an N-methyl-D-aspartate receptor antagonist, and the others are all cholinesterase inhibitors. These drugs are effective for about 6 to 12 months for about half of the patients who take them. However, these drugs have intrinsic limitations, including poor efficacy for chronic use and side effects.^{15,21-23} Therefore, there is an urgent need to develop novel therapeutic agents for the treatment of AD with improved outcomes and reduced side effects.

It has been recognized that coffee (Coff), caffeine (Caff) (1,3,7-trimethylxanthine or 3,7-dihydro-1,3,7-trimethyl-1Hpurine-2,6-dione) (Figure 1), and melatonin (Mel) (N-acetyl-5-methoxytryptamine) possess a variety of pharmacological activities, including antioxidative, antiapoptotic, antiautophagic, and neuroprotective effects.²⁴ Caff is the most widely consumed psychoactive substance and acts as an antagonist of adenosine A₁ receptors (A₁Rs) and A_{2A} receptors (A_{2A}Rs) at nontoxic doses.²⁵ At high concentrations, Caff, like theophylline, acts as a nonselective phosphodiesterase inhibitor, thereby leading to higher levels of the intracellular second messenger cyclic adenosine monophosphate. Mel is synthesized mainly by the pineal gland during the dark




Figure I Chemical structures of caffeine and melatonin.

phase of the circadian cycle and exhibits a number of physiological activities, including regulating circadian rhythms, inhibiting the oxidation of biomolecules and clearing free radicals, regulating intestinal motility and metabolism, and enhancing immunity.^{26,27} These effects are considered to be mediated by two specific Mel receptor subtypes, namely MT, and MT₂, which belong to G-protein-coupled receptors.²⁸ MT, receptors modulate neuronal firing, arterial contraction, and reproductive and metabolic functions, while MT, receptors regulate circadian rhythms of neuronal firing in the suprachiasmatic nucleus, induce vasodilation, and enhance immune responses.^{27,28} Mel-mediated responses elicited by activation of MT₁ and MT₂ receptors depend on cir time, duration, and mode of exposure to endogeno or exogenous Mel, and on functional receptor rensitiv Studies show that Mel levels are signific aly lo er in A patients compared with those in agestrol sub jects, and therefore, it is thought the a Me Acit is closely associated with aging and agenetic ted disease such as AD and Parkinson's disease.²⁹ Anine studies have shown that Coff, Caff, and Mercan prevent a related cognitive impairment, delay the progression of AD, and ameliorate AD symptoms.³¹⁻³ ur profous studies also demonstrated red in schondright function and directly that Mel imr bound to p to hibit A regation in AD mice,³⁵ and complation between Caff/Coff intake and that the was Aentia or delayed onset.32,36,37 We have found the risk of that mild cognize impairment patients with higher plasma Caff levels had delayed onset or lower risk of dementia during a 2-4 year follow-up period.³⁷ Both Caff and Mel act as blockers of BACE1 and γ -secretase and thus, reduce Aβ production.^{37–39}

Circadian rhythms are endogenously generated rhythms, with a periodicity of approximately 24 hours, that are driven by an endogenous circadian timekeeping system located in the suprachiasmatic nucleus of the hypothalamus.^{40–42} Circadian rhythms are generated as an output of the clock

gene cycle, produced by a series of interlocking transcriptional feedback/feed forward loops of a series of clock genes (eg, PER1/2, CRY1.2, CLOCK, and BMAL1). Such cycles drive the rhythmic expression of clock-controlled genes, and ultimately, such molecular cycles are translated into physiological and behavioral circadian rhythms. Circadian rhythms have regulatory effects on cell proliferation, cell metabolism, cell senescence, and cell death, involving a number of functional proteins, such as cyclin D1 and sirtuin 1.25,26 Circadian dysfunction also impacts negatively on immune, metabolic, and cardiovascular systems.^{43,44} Notet by increasing evidence indicates that circadian rhythme day an international role in the pathogenesis of many ailmen including urodegenerative diseases.^{41,45,46} It have een reconized the circadian rhythms have a strop association with h macotherapeutic effects, so called ronot crapy".^{43,44,47} This refers to the administration of drug t a cert a time of day, resulting in the high efficacy and the lowest side-effects, which profoundly influences the therapeutic outcomes in clinical set With circ Vian rhythms significantly disturbed in D, they may have a direct link to the pathogenesis of AD, nd accumulting evidence shows that chronotherapeutic roaches $r_{\rm A}$ y generate benefits in the treatment of AD.⁴⁶ studies are needed to elucidate the role of circa-Thus, shythms in the pathogenesis and therapy of AD.

To date, the effects of the combination of Coff or Caff and Mel on AD remain unclear, and the underlying mechanism for the beneficial effects of Coff, Caff, and Mel on AD is not fully understood. It has been suggested that reactive oxygen species (ROS), inflammation, and autophagy play a casual role in the development and progression of AD, with the involvement of glycogen synthase kinase 3β (GSK3 β), Tau, and Wnt3 α / β -catenin, resulting in A β accumulation and neuronal death.^{1,13,14,48–50} Therefore, we examined whether a combined use of Coff or Caff with Mel could give a synergistic or additive effect on A β generation in neurons via the regulation of ROS generation, inflammation, and autophagy.

Materials and methods Molecular docking

We employed the Discovery Studio program 3.1 designed by Accelrys Inc. (San Diego, CA, USA) to dock Caff and Mel into the active sites of ten human BACE1 structures (protein data bank [PDB] identification codes: 1FKN, 2OHU, 1W51, 2P4J, 2VKM, 4DH6, 3DV5, 2QU3, 3U6A, and 4FRS) as previously described by us.^{51–55} The crystal structure of human BACE1 was obtained from the Protein Data Bank (http://www.rcsb.org/pdb/). Before defining and editing the binding site, BACE1 was cleaned, modified, and prepared. During the preparation for Caff and Mel, the duplicate structures were deleted, and ionization change, Tautomer or isomer generation, Lipinski filter, and three-dimensional (3D) generator were all set true. Following the ligand preparation, Caff and Mel were docked into the binding site of BACE1. Electrostatic energy and van der Waals forces were considered during the docking process. For each defined van der Waals force or electrostatic probe, the interactions with all protein atoms were stored at predetermined grid points. For ligand atoms located between grid points, a trilinear interpolation was used to approximate the energies. A harmonic potential with the force constant of 300 kcal/mol was applied outside the grid boundary.^{51–55}

Chemicals and reagents

Caff and Mel were purchased from Sigma-Aldrich Corp (St Louis, MO, USA). Dulbecco's Modified Eagle's Medium (DMEM) was obtained from Corning Cellgro Inc. (Manassas, VA, USA). G418 (geneticin, a selective antibiotic), Dulbecco's phosphate-buffered saline (PBS), 3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), 4-(2hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPE) ethylenediaminetetraacetic acid (EDTA), and fetal bovin serum (FBS) were purchased from Sigma-Aldri Corp. The autophagy detection kit was bought fr I Enz Life Sciences Inc. (Farmingdale, NY, USA). Olyvin difluoride (PVDF) membrane was pre-hased m EMD rn blot sub. Millipore (Billerica, MA, USA). W ate was obtained from Thermo Fisher cienth. (Waltham, MA, USA). Primary antibodies gainst human Vrf2, LC3-I/II, n, phorphorylated p)-Tau/Tau, Beclin 1, Wnt3 α , β -cat p-GSK3β/GSK3β, p-A Akt PI3K/PI3K (p85/55), and pure yed from cell Signaling Techp-Erk1/2/Erk1/2 The antibody against nology Inc. everly MA, V human β -ax n was α ad from Santa Cruz Biotechnology Inc. (Dallas, ' /SA).

Preparation of Coff, Caff, and Mel

Maxwell House[®] regular Coff (Kraft Foods, Northfield, IL, USA) was purchased commercially and dissolved in autoclaved water. Briefly, 40 g of ground Coff was added to 300 mL autoclaved water. Coff solution was then heated to boiling, kept at boiling for 2 minutes, then filtered with a Coff filter into an autoclaved container. The concentration of Coff was determined according to the content of Caff. The concentration of 10 µM Coff is equivalent to 10 µM Caff. For "unconcentrated" Coff solution, 1.5 mL aliquots (containing 1.5 mg/mL Caff) were transferred into 2 mL tubes and stored at -20° C. Caff (7 mg) was dissolved in 1 mL PBS, and the stock solution was stored at -20° C. Coff and Caff were freshly diluted to predetermined concentrations with medium before use. Mel (10 mg) was dissolved in 1 mL ethyl alcohol and diluted to 1, 5, and 10 μ M with fresh medium before use (final ethyl alcohol concentration <0.01%, v/v). The chemical structures of Caff and Mel are shown in Figure 1.

Cell culture


Neuro-2a (N2a)/APP cells were derived from eably transfected N2a cells with Swedish Latant APPswand were maintained in a DMEM supremented with 10% FBS and 0.2 g/L G418 in 5% CO 4.737°C.

Drug treatment

We adopted the different of logical administration N2a/APP cells were treated with regimens in this stu Caff at M, 10 µM ff (equivalent to 10 μ M Caff), or t 1, 5, or 10 μ M alone or in combination. As shown in Mel e 2, cells we treated with Coff or Caff at 10 µM for 12 Fig hours the day blowed by Mel at 1, 5, or 10 μ M, for 12 ont in regimen 1 (Figure 2). The medium was hours in out after every 12-hour treatment. For regimen 2, W2 ells were treated with Coff or Caff at 10 µM or Mel at 1, , and 10 µM, alone or in combination, for 24 hours, from 7 in to 7 am the next day. In regimen 3 (Figure 2), cells were treated with Coff or Caff or Mel for 5 consecutive days with regimen 1 or 2. N2a/APP cells were treated with Coff or Caff at 10 μ M for 12 hours in the day, followed by Mel at 10 μ M for 12 hours in the night and continued for 5 consecutive days. When regimen 2 was incorporated in regimen 3, the cells were treated with the drugs for 24 hours. The medium was changed at every 12- or 24-hour drug treatment.

Cell viability assay

The viability of N2a/APP cells was examined using the MTT assay. Briefly, the N2a/APP cells (8,000/well) were seeded into 96-well plates and treated with 10 μ M Coff or Caff alone for 12 hours in the day, or with 1, 5, or 10 μ M Mel for 12 hours in the night, or in combination. Following the treatment, 10 μ L of MTT solution (5 mg/mL) was added to each well and incubated for 4 hours at 37°C. The medium was replaced with 100 μ L dimethyl sulfoxide (DMSO), and the absorbance was measured using a SynergyTM H4 Hybrid Microplate Reader (BioTek Inc., Winooski, VT, USA) at a wavelength of 570 nm.





Enzyme-linked immunosorbent assay (ELISA)

The concentration of A β 40/42 was measured usin. the Aβ40/42 Human ELISA kit (catalog numb KHB34 KHB3442; Life Technologies Corp, Car Joad, US according to the manufacturer's instructions can recognize both natural and st ns of human chetic A β 40/42, and the antibodies not crossct. According to the manufacturer's istruct. we used the kits to measure the extracellul levels of A in N2a/APP cells. $A\beta$ oligomer was measured using an The concentration g Aggregated β -Am d H an ELISA kit (catalog number KHB3491; Life Technologies Conjaccording to the manurure medium was collected facturer's Istruc ons. Th after N (APP) were treated with indicated regimens. Vere centrifuged at $100,000 \times g$ for 1 hour at The samp. 4°C prior to alysis. This oligometric form of A β (also known as amyloid β -derived diffusible ligand [ADDL]) can be separated from fibrillar and protofibrillar forms of aggregated A β by high speed centrifugation (ie, 100,000× g for 1 hour) or by size exclusion methods, as previously described.56 Sample preparation should therefore be carefully considered when using this assay. Centrifugation at $14,000 \times g$ for 10 minutes has been shown to minimize fibrils in aggregated A β -containing samples, while centrifugation at $100,000 \times g$ for 1 hour at 4°C has been shown to minimize

wrils and preofibrils.^{56,57} Size exclusion methods, such as get provided on chromatography or ultrafiltration, may also perove assay performance. The concentrations of interleukin (1L)-4, IL-12, and IL-10 were measured using ELISA kits (catalog number KHC0041/KHC0121/KAC1321; Life Technologies Corp). The concentration of interferon (IFN)- γ was determined using a Human IFN- γ ELISA Kit (catalog number EHIFNG; Thermo Fisher Scientific). The absorbance was detected at wavelength of 450 nm, using the SynergyTM H4 Hybrid Microplate Reader.

Western blot analysis

N2a/APP cells were washed with precooled PBS after treatment with indicated regimens and lysed with a lysis buffer consisting of 50 mmol HEPES at pH 7.5, 150 mmol NaCl, 10% glycerol, 1.5 mmol MgCl₂, 1% TritonTM X-100, 1 mmol EDTA at pH 8.0, 10 mmol sodium pyrophosphate, 10 mmol sodium fluoride, and the protease inhibitor cocktail. The supernatant was collected after the cell lysate was centrifuged at 14,000× g for 15 minutes at 4°C. Protein concentrations were measured using the BCA Protein Assay Kit. Equal amount of protein sample (30 µg) was resolved by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) sample loading buffer and denatured for 10 minutes at 95°C. Subsequently, the samples were electrophoresed on 7%–12% SDS-PAGE minigel and transferred onto Immobilon[®] PVDF membrane at 200 mA for 3 hours, at 4°C. Membranes were probed with indicated primary antibodies overnight at 4°C and then blotted with respective horseradish peroxidase-conjugated secondary anti-mouse or anti-rabbit antibody. Visualization was performed using a Bio-Rad ChemiDocTM XRS system (Bio-Rad Inc., Hercules, CA, USA) with enhanced-chemiluminescence substrate. Protein level was normalized to the matching densitometric value of the internal control, β -actin.

ROS measurement

Intracellular level of ROS was measured using 6-carboxy-2',7'-dichlorodihydrofluorescein diacetate (CM-H₂DCFDA) (InvitrogenTM; Life Technologies Corp, Carlsbad, CA, USA). Briefly, N2a/APP cells were seeded into black 96-well plates and treated with indicated regimens at different concentrations and different time points. The mean intensity of green fluorescence of 2',7'-dichlorofluorescein (DCF) was determined by the Synergy H4 Hybrid Microplate Reader, at 485 nm for excitation and 525 nm for detection. Fluorescence was measured every 3 minutes for 45 minutes using the Synergy H4 Hybrid Multi-Mode Microplate Reader. The protein concentration was measured to normalize the intracellular level of ROS.

Determination of autophagy using flow cytometry

To further explore the regulatory effect of foff, C Mel on N2a/APP cell death, we deter med the atophagy using flow cytometry. N2a/APP cell vere plated 6-well plates (Corning Inc, Corning, N, US, at an intensity of 4×10^5 cells/well. The cells **y** re treated with fresh medium, 12 hours in the day, followed by or Coff/Caff at 10 µM, Mel at 1, 5, and 10 μ M r 12 urs in the night. At the end of the treatment, the sells we trypsized and centrifuged In the cells. The cells were at $3,000 \times g$ for o minues, to p for containing 5% FBS (Enzo Life suspended 1× ass Sciences Inc.) collected by centrifugation. Following that, cells were respended in 250 µL of phenol red-free culture medium (Invictogen; Life Technologies Corp) containing 5% FBS. The diluted Cyto-ID® Green stain solution $(250 \,\mu\text{L})$ (Enzo Life Sciences Inc.) was added to each sample and mixed well. Cells were incubated for 30 minutes at 37°C, in darkness. After the incubation, cells were washed with 1× assay buffer and resuspended in 500 µL fresh 1× assay buffer. Thereafter, cells were analyzed using the green (FL1) channel of a flow cytometer (BD LSR II Analyzer; BD Biosciences, Franklin Lakes, NJ, USA).

Statistical analysis

Data were presented as mean \pm standard deviation. Comparisons of multiple groups were evaluated by one-way analysis of variance (ANOVA) followed by Tukey's multiple comparison procedure. *P*<0.05 was considered statistically different.

Results

Molecular interactions between Caff/Mel and BACEI

Both Caff and Mel are known blockers of DecE1 and reduce Aβ production.^{37–39} Cleavage of APP a the N-te ninus of the A β region by BACE1 and at the verminus by secretase is the first and key amyloid genic payway fro the substrate APP to generate peptides.^{13,13} T explore how Caff and Mel inhibit h pan L CE1, we first carried out docking experiments using the Discentery Studio program 3.1. After docine Caff or M the active sites of ten positions were generated for each BACE1 structures, action. CDOCKER interaction compo nzyme in. y ranges from around 17.6–34.6 kcal/mol (Figures 3 ener Table 1). Lech compound–enzyme complex with the and high CDOCK R interaction energy was selected, and the (2D) and 3D pictures of them were colwo-dime. When Caff and Mel were docked into the active sites lec the ten selected BACD1 structures, we observed different polecular interactions (Figures 3A–D and 4A–F, Table 1). he data showed that Caff bound to 1FKN and 3DV5 via the formation of a hydrogen bond at the site of Thr72 and Thr232, respectively. Caff formed three hydrogen bonds with 20HU via Lys238, Lys239, and Lys246, and generated two hydrogen bonds via Gln73 and Thr232. No electrostatic and π - π stacking interactions were observed with Caff and the BACE1 structures.

Mel could be readily docked into the active sites of the ten BACE1 structures (Figure 4A–F). Mel formed two hydrogen bonds with 2OHU via Phe108 and Thr232. It also formed multiple hydrogen bonds with 1W51 (via Gly13), 2P4J (via Gly230 and Thr232), 2VKM (via Asp32, Thr72, and Gly230), 3DV5 (via Asp32 and Gly230), 3U6A (via Gly11, Ser229, and Arg307), and 4FRS (via Asp93, Gly95, and Tyr259). Notably, Mel formed π - π stacking with Tyr71 of 2VKM.

These data demonstrate that both Caff and Mel could readily bind to the active sites of BACE1, mainly via hydrogen bond formation and less commonly, via π - π stacking with the key residue Tyr71. Many of the residues involved in hydrogen bond formation with Caff and Mel are located in the active

246



Figure 3 Molecular interactions between caffeine and the active site of BACEI structures.

Notes: (A) Caffeine binds to the active site of IFKN via hydrogen bond formation with Thr72; (B) Caffeine binds to the active site of 2OHU via hydrogen bond formation with Lys238, Lys239 and Lys246; (C) Caffeine binds to the active site of 2VKM via hydrogen bond formation with Gln73 and Thr232; and (D) Caffeine binds to the active site of 3DV5 via hydrogen bond formation with Thr232. The Discovery Studio 3.1 program (Accelrys Inc., San Diego, CA, USA) was used to dock caffeine into the active site of human BACEI structures.

Abbreviation: BACE, β -site amyloid precursor protein cleaving enzyme.





Figure 4 (Continued)





with Phe108 and Thr232; (f B) melatonin binds to the active site of 2P4J via hydrogen Notes: (A) Melatonin binds to the active site of 2OHU via hydrogen bond for VKM via hydrogen bond formation with Asp32, Thr72, and Gly230, and π - π stacking with bond formation with Gly230 and Thr232; (C) melatonin bind tive site Tyr71; (D) melatonin binds to the active site of 3DV5 via rogen bo formation with Asp32 and Gly230; (E) melatonin binds to the active site of 3U6A via hydrogen bond formation with GlyII, Ser229, and Arg307; and (F) m onin binds the active of 4FRS via hydrogen bond formation with Asp93, Gly95, and Tyr259. The Discovery Studio 3.1 program (Accelrys Inc., San Diego, CA, USA nto the active site of human BACE1 structures. use Abbreviation: BACE, β-site amyloid precurso enzyme.

site of BACE1, and thus, it is not a supplies that both Caff and Mel can act as competing inhibitors of ACE1.

Effect of Coff or Caff, plus Mel on N2a/ALD cells jability

cells with Coff or Caff at N2a/A After tr ament 10 µM 12 b nbination with Mel at 10 µM for another 12, urs, we measured the cell viability, using the MTT assay. Corpared with the vehicle control (medium), Mel at 1 μ M alone increased, by 18.4%, cell viability, and Coff (10 μ M) plus Mel at 1 or 5 μ M increased cell viability, by 25.0% and 35.7%, respectively (P < 0.001, by one-way ANOVA) (Figure 5A). Incubation of cells with the combination of Caff with Mel at 1, 5, or 10 µM resulted in a 34.3%, 42.0%, and 21.7% increase in cell viability, respectively $(P \le 0.001)$. In addition, treatment of cells with 10 μ M Caff increased 34.4% in cell viability (P < 0.001), but Coff at

 $10 \,\mu\text{M}$ did not affect cell viability (Figure 5B). These results demonstrated that Caff alone or in combination with Mel, and Mel at a low concentration, promoted the proliferation of N2a/APP cells.

Dynamic change of basal extracellular level of A β 40/42 in N2a/APP cells

N2a/APP cells were treated with G418 to induce A β 40/42 production prior to the treatment with different chorological regimens. We observed varying extracellular levels of A β 40/42 over 5 days and a peak at 24 hours (Figure 6). The extracellular level of A β 40 was 234.3, 1,801.7, and 56.6 pg/µL when cells were treated with G418 for 12 hours, 24 hours, and 5 days, respectively, with a maximum fold change of 31.8. For A β 42, the maximum fold change was 10.0. These findings demonstrate the dynamic and chronological changes of A β 40/42 in N2a/APP cells.

Compound	CDOCKER interaction energy (kcal/mol)	H-bond number	Residues involved in H-bond formation	Charge interactions	Residues involved in charge interactions	π-π stacking	Residues involved in π-π stacking
Caff							
IFKN	26.7893	L	O-Thr72	0	_	0	_
20HU	20.8538	3	H-Lys238 O-Lys239 O-Lys246	0	-	0	_
1W51	19.9758	0	-	0	-	0	_
2P4J	24.65	0	_	0	-	0	_
2VKM	27.7626	2	O-Gln73 O-Thr232	0	-	0	-
4DH6	22.18	0	_	0	-		-
3DV5	23.2694	I	O-Thr232	0	-	0	
2QU3	17.6425	0	_	0	-		
3U6A	19.6014	0	_	0	_	0	
4FRS	22.5468	0	_	0	-	0	_
Mel							
IFKN	34.4816	0	_	0		9	_
20HU	29.1	2	O-Phe108 O-Thr232	0	$\land \lor$	J	-
1₩51	31.3981	I.	O-Gly I 3	0	-	0	_
2P4J	33.3171	2	H-Gly230 O-Thr232	0	-	0	-
2VKM	36.5899	3	H-Asp32 O-Thr72 H-Gly230	0)	2	Tyr71
4DH6	32.1519	0	-	0	_	0	_
3DV5	34.1243	2	H-Asp32 H-Gly2 <u>3</u> 0		-	0	_
2QU3	26.2322	0		0	_	0	_
3U6A	31.441	3	Gly I I H-Ser225 Ar J7	0	-	0	-
4FRS	34.575	3	H-A-123 H-Glyx O-Tyr259	0	-	0	-

Table I Molecular interactions between Caff and Mel with human BACEI

Note: –, means none.

Abbreviations: BACE, β -site amy precursor protein cleave, enzyme; Caff, caffeine, Mel, melatonin.


Effect of Coff or Coff plus hel on the extracellular level of β 40/42 in N2a/API cells. The extracellular level of $A\beta$ 40/42 in N2a/APP

cells treated with regimen 1

First, we checked the affect of regimen 1 on the extracellular levels of A β 40/42 in N2a/APP cells. When the cells were incubated with Mel alone at concentrations of 1, 5, or 10 μ M for 12 hours, there was a concentration-dependent increase in the extracellular level of A β 40 in N2a/APP cells. Incubation of cells with 5 or 10 μ M Mel elevated the extracellular level of A β 40 by 1.6- and 2.3-fold, respectively (*P*<0.001, by one-way ANOVA) (Figure 7A and C). On the other

hand, treatment of cells with Coff or Caff alone showed distinct effects on the extracellular level of A β 40. When N2a/APP cells were treated with Coff at 10 μ M alone for 12 hours, the extracellular level of A β 40 was increased in comparison with the control cells (312.2 vs 234.3 pg/mL) (Figure 7A). When the cells were treated with Caff at 10 μ M alone for 12 hours, the extracellular level of A β 40 was only slightly decreased compared with the control cells (160.1 vs 234.3 pg/mL) (P>0.05) (Figure 7C).

We treated N2a/APP cells with the combination of 10 μ M each of Coff/Caff for 12 hours in the day, followed by another 12-hour treatment with Mel at 1, 5, or 10 μ M during the night. The extracellular level of A β 40 was






Figure 5 Effects of Coff/Caff plus Mel on N2a/APP cell viability. Notes: The cells were treated with Coff (**A**) or Caff (**B**) at 10 μM for 12 hours in the day, followed by Mel 40, 5, a 10 μ 1 for a furth 12 hours in the night. The cell survival was determined by the MTT assay. ***P<0.001, by one-way ANOVA. Abbreviations: ANOVA, analysis of variance; APP, amyloid precursor protein; Caff, caffeine; Coff, coffee; McL Patonin; MTT, 3-1, adjine sylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; N2a, Neuro-2a.

concentration-dependently increased. Compared with the control cells, incubating cells with Coff plus 5 or 10 μ M Mel increased the extracellular level of A β 40 by 1.3- and 2.0-fold, respectively (P<0.001, by one-way ANV-0.0) (Figure 7A). Treatment of cells with Caff plus 5 or 10 μ M Mel resulted in a 2.0- and 4.0-fold increase in the extra dular level of A β 40, respectively (P<0.001, by one-way ANV-0.0) (Figure 7C). Incubation on the cells with Caff for 12 hours in the day followed by Med 12 hours in




Figure 6 Changes in extracellular basal levels of A\beta40/42 levels in N2a/APP cells over 5 days.

Notes: The cells were treated with the selective antibiotic G418 and the supernatants collected for A β determination using ELISA kits. ***P<0.001, by one-way ANOVA. **Abbreviations:** A β , amyloid- β ; ANOVA, analysis of variance; APP, amyloid precursor protein; ELISA, enzyme-linked immunosorbent assay; G418, geneticin; N2a, Neuro-2a.

te night more significantly increased A β 40 levels than vith Mel alow: In addition, exposure of N2a/APP cells to v 10 μ M Del with Caff increased the extracellular level of Approx.2- and 1.7-fold, respectively, compared with resure to Mel alone (*P*<0.001, by one-way ANOVA) (Figure 7C).

Mel alone significantly increased the extracellular level of AB42 in a concentration-dependent manner in N2a/APP cells (Figure 7B and D). Compared with the control cells, incubation of cells with 5 or 10 µM Mel resulted in a 5.8- and 8.0-fold increase in the extracellular A β 42 level, respectively (195.5 vs 33.9 pg/mL, and 270.4 vs 33.9 pg/mL) (P<0.001, by one-way ANOVA) (Figure 7B). However, treating cells with Coff/Caff alone for 12 hours led to a decrease in the extracellular level of AB42 compared with the control cells (26.2/17.0 vs 33.9 pg/mL) (Figure 7B and D). Furthermore, we treated N2a/APP cells with Coff/Caff for 12 hours in the day, followed by Mel for another 12 hours in the night. There was a 3.9- and 4.0-fold increase in the extracellular level of A β 42 after cells were treated with 10 μ M Coff followed by 5 or 10 μ M Mel, respectively (P<0.001, by one-way ANOVA) (Figure 7B). Moreover, incubation of cells with 10 μ M Caff followed by 5 or 10 μ M Mel resulted in a 3.8- and 6.0-fold increase in the extracellular level of AB42, respectively (P < 0.001, by one-way ANOVA) (Figure 7D). These results demonstrated that Mel alone considerably increased the extracellular levels of A β 40/42 in N2a/APP cells and




Figure 7 Effects of Coff/Caff plus Mel on the extracelly $A\beta^{2}$, D_{1} by S_{1} in N2a/An, cells treated with regimen 1. **Notes:** N2a/APP cells were treated with Coff (**A** and **b**) or Caff (**b** and **D**) at 10 μ M for 12 hours in the day, followed by Mel at 1, 5, or 10 μ M for another 12 hours in the night. The extracellular level of A β 40/42 was detected by ELISA. * (0.001, by one-way ANOVA. **Abbreviations:** A β , amyloid- β ; ANOVA, and its of thance; APP, amyloc precursor protein; Caff, caffeine; Coff, coffee; ELISA, enzyme-linked immunosorbent assay; Mel, melatonin; N2a, Neuro-2a.

that Coff or Caff at relatively high concentration (10 μ M) decreased extracellular wells of $\chi\beta40/42$ to a greater extent, than did Mel at 1 = 5 μ M.


The extract llular level of $A\beta 40/42$ in N2a/APP cells treated the regimen 2

Next, in order to explicit the effect of different chorological regimens of Coff/Cair plus Mel, N2a/APP cells were treated with Coff/Caff plus Mel for 24 hours, from 7 am to 7 am the next day (regimen 2). In comparison with the control cells, there was no significant difference in the extracellular level of Aβ40 and Aβ42 when cells were exposed to Coff, Caff, or Mel alone for 24 hours (P>0.05) (Figure 8A–D). However, incubation of cells with 10 µM Coff plus 5 or 10 µM Mel increased by 1.3- and 1.2-fold the extracellular level of Aβ40, respectively (2,359 and 2,173 vs 1,802 pg/mL) (P<0.001,

by one-way ANOVA), and by 1.5-fold that of A β 42 (491.5 vs 314.6 pg/mL) (P<0.001, by one-way ANOVA) (Figure 8A and B). Treating cells with 10 μ M Caff plus 5 or 10 μ M Mel resulted in a 1.2-fold increase in the extracellular level of A β 40 (2,224 and 2,117 vs 1,802 pg/mL) (P<0.001, by one-way ANOVA), respectively, and 1.33-fold that of A β 42 (451.7 vs 314.6 pg/mL) (P<0.001, by one-way ANOVA) (Figure 8C and D).

The extracellular level of A $\beta40/42$ in N2a/APP cells treated with regimen 3

Furthermore, we treated cells with Coff/Caff with or without Mel combination, for 5 consecutive days with regimen 1 or 2. The data for the changes of the extracellular levels of A β 40/42 are shown in Figure 9A–H. The extracellular level of A β 40/42 was lower than that in regimens 1 and 2.



Notes: N2a/APP cells were treated with Coft **A** and **B**) \sim aff (**C** and **D**) at 10 μ M, plus Mel at 1, 5, or 10 μ M for 24 hours, from 7 am to 7 am the next day. The extracellular level of Aβ40/42 was determined by ELSA. **P<0.001, by one-way ANOVA. **Abbreviations:** Aβ, amyloid-β; ANOV analy: of variance; API byloid precursor protein; Caff, caffeine; Coff, coffee; ELISA, enzyme-linked immunosorbent assay; Mel, melatonin; N2a, Neuro-2a.

In 10 μ Mel for 12 nours in the night Incubation of cells y following 10 µM C for hours in the day for 5 days sig- $\sqrt{6}$, the *e* racellular level of A β 42 nificantly red d, by 001, by one-way ANOVA) (126.9 vs 49.2 j (mL)(Figure B). Tre tof cells with 10 µM Mel for 12 hours Nowing Caff 10 µM for 12 hours in the day in the night for 5 days also ignificantly decreased, by 8% and 13%, the extracellular lever of A β 40 (52.7 vs 56.9 pg/mL) (P<0.001, by one-way ANOVA) (Figure 9E) and A β 42, respectively (130.5 vs 149.2 pg/mL) (P<0.05, by one-way ANOVA) (Figure 9F). There were only slight changes in the extracellular A β 40 level when N2a/APP cells were treated with Caff, Coff, and Mel alone (Figure 9A-H). No significant difference was observed in the extracellular level of A β 40/42 in N2a/APP cells treated with Coff/Caff plus Mel together for 24 hours over 5 days (Figure 9C, D, G, and H).

Effect of Coff or Caff, plus Mel on the extracellular level of A β oligomers in N2a/APP cells

Age-dependent accumulation of A β in the brain from "normal brain aging" to AD is a complicated process. It has been proposed that the intracellular level of A β oligomers may indicate the progression of AD.⁵⁸ Therefore, we examined the extracellular level of A β oligomers in N2a/APP cells. Our data showed that there was only a slight reduction in the level of A β oligomers in N2a/APP cells treated with Coff for 12 hours, followed by Mel for 12 hours (689.8 vs 759.3 pg/mL) (Figure 10A). Incubation of cells with 10 μ M Mel for 12 hours in the night following Caff 10 μ M for 12 hours in the day reduced, by 22%, the extracellular level of A β oligomers in N2a/APP cells (589.5 vs 759.3 pg/mL)





Figure 9 (Continued)






Figure 9 Effects of Coff/Caff plus Mel on the extracellular Aβ40/42 levels in N2a/APP cells treated with Regime 3. **Notes:** N2a/APP cells with 10 μM Coff (**A–D**) or Caff (**E–H**) for 12 hours or 24 hours, followed by 10 μM cell for 12 on thours for consecutive days. The extracellular level of Aβ40/42 was determined by ELISA. **P*<0.05 and ****P*<0.001, by one-way ANOVA. **Abbreviations:** Aβ, amyloid-β; ANOVA, analysis of variance; APP, amyloid precursor protein; Caff on reins, poff, coffee; ELISA, azyme-linked immunosorbent assay; Mel, melatonin; N2a, Neuro-2a.

(P<0.001, by one-way ANOVA) (Figure 10B). However, there was only a slight reduction of extracellular A β oligomer levels in N2a/APP cells treated with Caff alone (658.3 vs 759.3 pg/mL) (P>0.05), whereas Coff elicited an opposite effect on the level of A β oligomers (Figure 10A and L

Coff or Caff, plus Mel did not change the expression levels of cytokines in N2a/APP cells

The buildup of A β aggregate to AD is for wed by the formation of intracellular net officiency tangles and activation of neuroinflammator responses. Mel and Coff/Caff may prevent the cellular damage induced by the exposure of neurons to A β , which is associated with neuroinflammation.³⁷ Therefore, the next determined the production of T helps cell (Th)1-rected L-12 and IFN- γ and Th2-related to 4 and to 10 in N2a/APP cells. Treatment of N2a/APP cells at 10 μ M did no may e a significant effect on the levels of these cytokines in N2a, APP cells (*P*>0.05, by one-way ANOVA) (Figure 11A–H).

Coff or Caff, plus Mel had no effect on autophagy of N2a/APP cells


Both autophagy and apoptosis are basic physiologic processes contributing to the maintenance of cellular homeostasis, involving a sequential set of events, including double membrane formation, elongation, vesicle

turation, and final, delivery of the targeted materials the lysosocies.^{60–62} Autophagy can remove and eliminate maged or nelles to protect cells against cell death. ulation of autophagy plays a pivotal role in the etiolgy and progress of neurodegenerative disorders.^{49,50} It has been, eported that Mel-induced autophagy protected against neuronal apoptosis in rats.⁶³ In order to further unveil the underlying mechanisms for the beneficial effects of Caff, Mel, and Coff on AD, the autophagic effect was examined using flow cytometry. In N2a/APP cells treated with regimen 1, there was only a slight increase in cellular autophagy (Figure 12A-C), and there was no significant alteration in the expression of the autophagy-associated markers Beclin 1 and LC3-I/II (Figure 12D-H). These results suggest that autophagy may play a negligible role in the beneficial effects of Caff, Mel, and Coff on AD.

Coff or Caff, plus Mel reduced oxidative stress in N2a/APP cells via Nrf2 pathway

Oxidative stress has a notorious role in the development and progression of AD;^{1,21,64,65} oxidative stress interacts with macromolecules, such as DNA and proteins, resulting in cellular dysfunction and eventually leads to cell death. Antioxidation is proposed to be capable of ameliorating the symptoms of AD.⁶⁶ As such, the antioxidative effects of Coff, Caff, and Mel were examined in N2a/APP cells. Treatment of cells with 10 μ M Coff or Caff for 12 hours in the day, combined with 10 μ M Mel for 12 hours in

Dovepress






Figure 10 Effects of Coff/Caff plus Mel on extracellular $A\beta$ oligomer levels in N2a/APP cells treated with regimen 1. **Notes:** N2a/APP cells were treated with Coff (**A**) or Caff (**B**) at 10 μ M for 12 hours in the day, followed by Mel at 1, 5, 10 μ M for another 12 hours in the night. The extracellular level of $A\beta$ oligomer was determined by ELISA. ***P<0.001, by one-way ANOVA. **Abbreviations:** A β , amyloid- β ; ANOVA, analysis of variance; APP, amyloid precursor protein; Caff, caffeine; Cur, coffee; ELISA, tryme-lined immunosorbent assay; Mel, melatonin; N2a, Neuro-2a.

the night significantly reduced, by 20.2% and 17.5%, the intracellular levels of ROS, respectively (P<0.05 and P=0.001, respectively, by one-way ANOVA) (Figure 13A and B). Since Nrf2 controls the basal and induced expre sion of an array of antioxidant response element-depende genes to regulate the physiological and pathophysiological outcomes of oxidant exposure,^{67,68} we further .eller ined the effects of Coff/Caff and Mel on its expression in N2a/ APP cells. We found that incubation cells wi Coff/Caff in the day and 10 μ M M $_{-}$ in the n t significantly decreased, by 72.7% and 4 9%, he express level of Nrf2, respectively (P < 0.0001, by one way ANOVA) alts suggest that e beneficial (Figure 14A–C). These r effects of Coff/Caff and Mel a AD may be ascribed, at least in part, to antioxida activity s d the involvement ling of Nrf2-mediat thw

Coff or Off cluster downregulates Wnt3 α expression but upregulated β -catenin expression in N2a/APP cells

Dysfunctional Wnt/ β -catenin signaling plays an important role in the pathogenesis of AD.⁶⁹ In the present study, we examined the effect of the combinations of Coff/Caff with Mel on the expression of Wnt3 α and β -catenin in N2a/APP cells. The data showed that treatment of cells with Coff/ Caff plus 1, 5, or 10 μ M Mel decreased, by 20.3%, 29.3%, and 28.0%, and 23.8%, 67.0%, and 77.0%, the expression of Wnt3 α , respectively, compared with the control cells

of 0.001, by one way ANOVA) (Figure 15A–E). (P <was an inchase in the expression of β -catenin when The vere treated ith the two combinations. In comparison cells ells, Coff plus 1, 5, or 10 µM Mel increased, with the ntrol 7%, 53.0%, and 33.3%, respectively, the expression β-cathin; and Caff plus 5 or 10 μM Mel increased, by 27.9% and 41.3%, respectively, the expression of catenin (P < 0.001, by one-way ANOVA) (Figure 15A–E). These data clearly demonstrate that Coff/Caff plus Mel or Mel alone concentration-dependently downregulated the expression of Wnt3 α/β -catenin in N2a/APP cells, probably contributing to the protective effects of Coff/Caff and Mel on AD.

Coff or Caff, plus Mel inhibited GSK3 β , Akt, PI3K p55, and Tau phosphorylation but enhanced PI3K p85 and Erk1/2 phosphorylation in N2a/APP cells

GSK3 is a ubiquitously expressed serine/threonine protein kinase that plays a key role in the pathogenesis of AD.⁷⁰ GSK3 phosphorylates Tau at serine and threonine, contributing to A β production and A β -mediated neuronal death.⁷⁰ Our data showed that the phosphorylation level of GSK3 β was significantly reduced, by 17.2% with Coff, and by 33.5% in Caff at 5 μ M; and by 61.5% with Coff, and by 52.7% with Caff at 10 μ M for 12 hours in the day plus Mel at 10 μ M for 12 hours in the night compared with the control cells, respectively (*P*<0.001, by one-way ANOVA) (Figure 16A–C).




Figure II (Continued)




Figure 11 Effects of Com/call plus held on cytokine levels in N2a/APP cells treated with regimen 1. **Notes:** N2a/APP cells were treated with Coff (**A**–**D**) or Caff (**E**–**H**) at 10 μ M for 12 hours in the day, followed by Kel at the output M for an ther 12 hours in the night. The cytokine levels were determined by ELISA. **Abbreviations:** A β , amyloid- β ; ANOVA, analysis of variance; APP, amyloid precursor protein; Caff, caffeine; the coffee; ELISA, the method immunosorbent assay; IFN, interferon; IL, interlevkin; Mel, melatonin; N2a, Neuro-2a.

Coff (10 μ M) plus 5 or 10 μ M Mel elevated 19.6% and 7.0% of the ratio of p-PI3K over PI3K p85, respectively; and Caff (10 µM) plus 1, 5, or 10 µM Mel increased 51.0%, 80.3%, and 80.4% of the ratio of p-PI3K over PI3K p85, respectively (P < 0.001, by one-way ANOVA) (Figure 16A– Coff at 10 μ M plus 1 μ M Mel elevated 51.7% of the ratio of p-PI3K over PI3K p55, but this ratio was decreased 31.4% and 73.1% when the concentration of Mel wa increa d to XI. 5 or 10 μ M, respectively (P<0.001, by one way A) (Figure 16A–C). In addition, Caff at 1/ aM p. µM Mel increased 47.5% of the ratio of p-P-C over PI3N 55, but Caff at 10 µM plus 10 µM Mel decrease 23.5% of the ratio (P < 0.001, by one-way ANC A) (Figure 16. C). However, Caff at 10 µM plus 5 µM el only lightly increased the ratio of p-PI3K over PI3K p. $(P \ge P)$ J5).

ombination of Coff/Caff with Exposure of *p* to the b sphorylation of Erk1/2 Mel led to a .ncrea in the (P < 0.001, v one)ANOVA) (Figure 16A–C). On e phosphorylation level of Akt was sigthe other hand, 4.8%/30.1% for Coff/Caff plus Mel at nificantly reduced, 1 μ M; 27.5%/43.6% for Coff/Caff plus Mel at 5 μ M; and 42.9%/52.0% for Coff/Caff plus Mel at 10 µM, in N2a/ APP cells treated with Coff/Caff at 10 µM for 12 hours in the day plus Mel at 1, 5, or 10 μ M for 12 hours in the night compared with the control (P < 0.001, by one-way ANOVA) (Figure 16A–C). In addition, incubation with 5 or 10 μ M Mel in the night, followed by Coff/Caff at 10 µM in the day significantly reduced 51.5%/53.3% for Coff/Caff plus Mel at 5 µM; and 61.5%/89.2% for Coff/Caff plus Mel at

c phosphore tion levels of Tau (P < 0.001, by 10 µM ay ANOVA) (Figure 16A–C). The same combination one icantly inhi ted 42.94% (Coff)/52.2% (Caff) of the sign vel of Akt (P < 0.01 or 0.001, by one-way phos orylation/ ANOVA, _____ure 16A–C). Taken together, these results rated that Coff or Caff plus Mel inhibited GSK3 β , der kt, PI3K p55, and Tau phosphorylation but enhanced PI3K 85 and Erk1/2 phosphorylation in N2a/APP cells, probably ontributing to the neuroprotective and antiamyloidogenic effect. The reason for the opposing effect of Coff or Caff, plus Mel on PI3K p55 and p85 in N2a/APP cells is unknown, depending on the concentrations of Mel.

Comparison of the neuroprotective and antiamyloidogenicity-enhancing effects between Coff and Caff, plus Mel in N2a/APP cells

Based on above findings, both Coff and Caff chronologically enhanced the antiamyloidogenic activity of Mel in N2a/APP cells. Finally, we compared the beneficial effects of these two combinations (Coff plus Mel vs Caff plus Mel). As shown in Table 2, two combinations showed comparable neuroprotective and antiamyloidogenic effects in N2a/APP cells, but there were some differences in the magnitude of the effects on cell viability, A β 42 oligomerization, and the phosphorylation of several key regulators. Caff plus Mel significantly increased cell viability but decreased the extracellular level of A β oligomers; whereas Coff plus Mel did not exhibit significant effects (Table 2). Caff plus




Figure 12 (Continued)




Figure 12 Effects of Coff/Caff plus Mel on autophagy in N2a/APP cells treated with regimen 1.

Notes: N2a/APP cells were treated with Coff or Caff at 10 μ M for 12 hours in the day, followed by Mel at 1, 5, or 10 μ M for another 12 hours in the night. (A) Flow cytometric analysis of autophagy; bar graphs showing the autophagy level with Coff and Mel (B), or Caff and Mel (C); (D) representative blots of LC3-I/II and Beclin 1; and bar graphs showing the relative expression level of Beclin 1 (E, F) and LC3-II (G, H) after treatment with Coff/Mel (E, G) or Caff/Mel (F, H). **Abbreviations:** APP, amyloid precursor protein; Caff, caffeine; Coff, coffee; FSC-A, flow cytometric channel detecting by a photodiode detector; Mel, melatonin; N2a, Neuro-2a; SSC-A flow cytometric channel detecting by a photomultiplier detector.




Figure 14 Effects of Coff/Caff plus Mel on the expression level of Nrf2 in N2a/APP cells treated with regimen 1.

Notes: N2a/APP cells were treated with Coff or Caff at 10 μ M for 12 hours in the day, followed by Mel at 1, 5, or 10 μ M for another 12 hours in the night. Cells were harvested, lysed, and subjected to SDS-PAGE. The target protein was probed using corresponding primary antibody. β -actin was used as the internal control for value normalization. (A) Representative blots of Nrf2; and bar graphs showing the relative expression level of Nrf2 in response to Coff and Mel (B), and Caff and Mel (C).

Abbreviations: ANOVA, analysis of variance; APP, amyloid precursor protein; Caff, caffeine; Coff, coffee; Mel, melatonin; N2a, Neuro-2a; SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis.

Dovepress




Figure 15 Effected Coff/Caffinus Mel on the oppression of Wnt3 α and β -catenin in N2a/APP cells treated with regimen 1. **Notes:** N2a/APP cells were first with Coff or Caff at 10 μ M for 12 hours in the day, followed by Mel at 1, 5, or 10 μ M for another 12 hours in the night. Cells were harvested, lysed, an upbridged to SDS and E. The target proteins were probed using corresponding primary antibodies. β -actin was used as the internal control for value normalization. (**A**) Representative blots of Wnt3 α and β -catenin; and bar graphs showing the relative expression level of Wnt3 α and β -catenin in response to Coff and Mel (**B**, **D**), and Caff and Men (**E**). **P<0.01 and ***P<0.001, by one-way ANOVA.

Abbreviations: ANOVA, this of variance; APP, amyloid precursor protein; Caff, caffeine; Coff, coffee; Mel, melatonin; N2a, Neuro-2a; SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis.

Mel more significantly increased the extracellular level of monomeric A β 42 than did Coff plus Mel. Compared with the combination of Coff plus Mel, Caff plus Mel showed more potent enhancing effects on the phosphorylation of PI3K and Erk1/2. In addition, Caff plus Mel showed a stronger regulatory effect on Wnt3 α than did its counterpart. Overall, Caff had a stronger enhancing effect on the antiamyloidogenic activity of Mel than Coff in N2a/APP cells, suggesting that the Caff in Coff was the main active component that enhanced the antiamyloidogenic activity of Mel and that other components in Coff might compromise the antiamyloidogenic effects of Caff.

Discussion

AD is characterized by the presence of numerous extracellular plaques and intracellular neurofibrillary tangles, and




Figure 16 (Continued)




Figure 16 (Continued)

264




Figure 16 Effects of Coff/Caff plus Mel on the levels of p-Tau/Tau, p-GSK3β/GSK3β, PI3K/PI3K p85, p-Akt/Akt, p-Erk1/Erk1 and p-Erk2/Erk2 in N2a/ APP cells treated with regimen 1.

Notes: N2a/APP cells were treated with Coff or Caff at 10 μ M for 12 hours, followed by I 1, 5, and 10 for another 12 hours. Cells were harvested, lysed, and subjected to SDS-PAGE. The target proteins were probed using corresponding primary ibodies.β-acti e internal control for value normalization. (A) Representative blots of p-Tau/Tau, p-GSK3β/GSK3β, p-PI3K/PI3K p85, p-PI3K/PI3K p55, p-Akt/A k1/2/Erk1/2, ar graphs showing the relative expression level of p-Tau/Tau, p-GSK3 β / GSK3β, p-PI3K/PI3K, p-Akt/Akt, p-Erk1/Erk1 and p-Erk2/Erk2 after treatment (B) or Caff and Mel (C). **P<0.01 and ***P<0.001, by one-way ANOVA. ith Co Abbreviations: ANOVA, analysis of variance; APP, amyloid precursor pro Ca off, coffee; Mel, melatonin; N2a, Neuro-2a; p, phosphorylated; SDS-PAGE, affe sodium dodecyl sulfate polyacrylamide gel electrophoresis.

Regimen	Parameter	Ence	Change (Coff + Mel 10 μM)	Change (Caff + Mel 10 μ M)	
I	МТТ	$\downarrow\uparrow$	3.95% decrease without statistical	21.7% increase with statistical	
			significance	significance***	
	Αβ40	▼ ↑	2.04-fold***	4.02-fold***	
	Αβ42	\uparrow	3.95-fold***	5.91-fold***	
	Aβ c'homer	\downarrow	0.09%	22%***	
	R	\downarrow	20.15%***	17.48%***	
	Nrf2	\downarrow	72.65%***	41.87%***	
	Akt/Ak	\downarrow	42.94%**	52.02%***	
	ρ Ι SK3β/G	\downarrow	61.43%***	52.67%***	
	(True/Tau	\downarrow	61.42%***	89.12%***	
	р-РІЗК/Різк _Р 85	\uparrow	6.96%***	80.43%***	
	p-Erk1/Erk1	\uparrow	4.2%	51.28%***	
	Erk2/Erk2	\uparrow	50.20%***	197.50***	
	Wnt3a	\downarrow	27.9%**	73.9%***	
	β-catenin	\uparrow	33.27%***	41.27***	
2	Extracellular Aβ40 level	\uparrow	1.21-fold***	1.18-fold***	
	Extracellular A β 42 level	\uparrow	1.45-fold***	1.33-fold**	
3	Extracellular Aβ40 level (12 h)	\uparrow	I.02-fold	0.93-fold***	
	Extracellular A β 42 level (12 h)	\uparrow	0.83-fold***	0.87-fold*	
	Extracellular A β 40 level (24 h)	\uparrow	0.96-fold	0.93-fold	
	Extracellular A β 42 level (24 h)	\uparrow	I.25-fold	I.I3-fold	

Table 2 A comparison of the antiamyloide inic effect of Coffee Caff, plus Mel in N2a/APP cells

Notes: The results are compared with the control cells. *P<0.05; **P<0.01; and ***P<0.001, by one-way ANOVA. Down and up arrows mean decrease and increase, respectively. **Abbreviations:** A β , amyloid- β ; ANOVA, analysis of variance; Caff, caffeine; Coff, coffee; GSK3 β , glycogen synthase kinase-3 β ; Mel, melatonin; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; p, phosphorylated; ROS, reactive oxygen species. extracellular A β accumulation and Tau hyperphosphorylation and aggregation are the hallmarks of AD.^{1,15,21} Excessive extracellular A β consequently triggers the hyperphosphorylation and aggregation of Tau protein. Inhibition of the production and increase in the clearance of A β are the promising strategies to treat AD.^{1,15,21} In the present study, various chronological regimens of the combination of Caff or Coff plus Mel showed inhibitory effects on the formation of A β oligomers, ROS generation, and Tau signaling pathway in N2a/APP cells, which may partially explain their neuroprotective effect in AD mice.

Our data clearly show that the combination of Coff or Caff, with Mel had more potent antiamyloidogenic effects than did a single agent, and Caff showed a larger antiamyloidogenic activity than did Coff in N2a/APP cells. There is epidemiological evidence that supports therapeutic benefits of Coff consumption against development of AD. In a population-based study with follow-up of 21 years, people who drank three to five cups of coffee per day during midlife were observed to have a 65% lower risk of developing AD later in life as compared with those who drank little or no Coff.⁷¹ A meta-analysis of pooled epidemiological studies also reported protective effects of Coff consumption against AD.72 On the other hand, decaffeinated coffee may have limit protective effects against AD, implicating the important rol of Caff as the major active component against AD we have previously observed potentiating effect of of er unk own Coff components on Caff's benefits again, AD.³⁷ studies are required to investigate and ompa e effects on AD, and of caffeinated and decaffeinated C e doseresponse and dose-toxicity relationships of caffeinated Coff and Caff in the treatment of D should be tablished.

proteclytic cleavage of APP BACE1 catalyzes # between Met and Aspensidue in the sequence stretch of Lys670-Met671-BACE¹ reinternalized from 672.¹ .o earl nd can be recycled back the cell surface endoso. i loring the long half-life of BACE1 to the cell **s** face. C (~9 hours) and ecycling rate, BACE1 moves between the cell surface and the endosomal system many times through the course of its life span.¹⁸⁻²⁰ A double mutant APP with Asn670-Leu671-Asp672 sequence at the cleavage site, found in Swedish patients with early onset AD, is a more efficient substrate in vitro than the wild-type protein and is the cause for the disease in this family. Transgenic mice carrying these mutations showed memory deficit, with a fivefold increase in A β 40 and a 14-fold increase in A β 42/43.⁷³ Our molecular docking results showed that Caff could bind to BACE1 via the formation of hydrogen bonds at Thr72, Gln73, Thr232,

Lys238, Lys239, and Lys246. Mel could also bind to BACE1 via hydrogen bond formation at Gly11, Gly13, Asp32, Thr72, Asp93, Gly95, Phe108, Ser229, Gly230, Thr232, Tyr259, and Arg307. Furthermore, Mel formed π - π stacking with Tyr71 of BACE1. BACE1 is a monomeric protein, with the catalytic site containing the two aspartate residues, Asp32 and Asp228, located between the N- and C-terminal domains. BACE1 has two aspartic protease active site motifs, DTGS (residues 93-96) and DSGT (residues 289-292), and mutation of either aspartic acid renders the enzyme inactive. The active site is covered by a flexible antiparallel β have between Val67 and Glu77 (commonly known as the ap") that rms a large portion of the binding pocket and fers shieldin from the solvent to facilitate efficient azymat, catalysi ⁴ BACE1 becomes activated within the late Golgi artments and endosomes/lysosomes. Le acide conditions optimal for the enzyme (pH of $4\frac{5}{6}$) indices that an unibitor containing a d show a high affinity. basic amine win NKa of ≥6. Tyr71 is a key residue in the flap, which adopts a conformation compentary to the substrates/ tors bound in the active site.⁷⁴ The changing position inhi flap relative o the catalytic dyad provides a means for oft the s. strates/in/ bitors to get access into the active site.⁷⁴ The come. non of BACE1 is defined as "closed" in the bound form when the Tyr71 side chain hydroxyl on in e flap is within hydrogen bonding distance to the nitrogen of the Trp76 indole side chain (with a distance of 3.3 Å), at the hydrogen bond in the β -strands between Tyr71 and Gly74 is not formed, which physically separates the S1 and S2' subsites. Also, the side chain of Arg128 occupies a space between Arg128 and Tyr198 in the inactive form. In contrast, the conformation of BACE1 is defined as "open" when the flap moves away from the catalytic Asp, the hydrogen bond between the flap residues Tyr71 and Trp76 is not formed, and Tyr71 does not occupy the position between the S1 and S2' subsites.⁷⁴ In the open form of BACE1, Tyr71 may adopt a unique orientation to form a hydrogen bond between the backbone carbonyl of Lys107, and the hydrogen bond in the β-strands between Tyr71 and Gly74 is formed.⁷⁵ As such, conformational change in the flap must take place upon binding of the substrate/inhibitor to the active site and may participate kinetically in substrate binding in the closed conformation and product release in the open conformation. Both Caff and Mel are known BACE1 inhibitors.³⁷⁻³⁹ BACE1 belongs to the pepsin family of the aspartyl protease superfamily and has the most sequence identity with BACE2 (52%), cathepsin D (29%), pepsin (27%), cathepsin E (27%), and renin (24%).¹⁸⁻²⁰ To date, a number of BACE1 inhibitors

have been developed and tested at the preclinical stage; several of them, including LY2886721, E-2609, MK-8931, RG-7129, HPP-854, and AZD-3839, have been evaluated in Phase I studies. The open form of the BACE1 enzyme appears to offer a more drug-like binding cavity than does the closed form of the enzyme. The inhibitors that target the open-form BACE1 are of low molecular weight; high binding efficiency; low polar surface area with improved metabolic stability, P-glycoprotein efflux, and oral bioavailability, and A β -lowering activity, in animal models and in human clinical trials.^{20,76}

The monomeric A β (molecular weight ~4 kDa) is generated mainly in neurons from APP (molecular weight ~120 kDa) via sequential scission by β - and γ -secretase.^{13,17,77,78} A β is a heterogeneous mixture of peptides with distinct solubility, stability, and biological and toxic properties. y-Secretase cleaves APP at different positions, giving rise to a variety of peptides, of which Aβ43, Aβ42, Aβ40, Aβ38, and Aβ37 can be detected in cell culture and body fluids.^{13,17,77,78} The heterogeneity of A β is enhanced by other enzymes, such as aminopeptidases, glutaminyl cyclase, isomerases, and protein kinases, resulting in a mix of more than 20 A β peptides that all participate in putative $A\beta$ functions in the normal brain and in oligomerization and fibrillization in AD. A β 40 is continuously and abundantly produced in bot the normal and AD brain, whereas other A β peptidener for at lower levels. A β 40 and A β 42 are present in pl ues, ai anticated increased A β 40 and/or A β 42 levels keep beep in the pathogenesis of AD.^{1,15,21,7} A β elf-assemble ular oligon into fibrils, protofibrils, and structures. Amyloid plaques might exist in equilibrium with digomeric forms of A β , consisting cross- β -sheep its of A β peptides that are arranged to form apploid fibrils. The monomeric form of A β has no vtot acity toward neurons, whereas neuro vic, resulting in cellular dysfunction Aß oligomers .th.77-8 and cell d may be metastable interme- β olig diates the pa to an insoluble, cross- β -sheet-based fiber. $A\beta$ h mers, oligomers, and fibrils exist in a complex equilibrium, s sitive to numerous external factors. Loss of function and decrease in the number of neurons eventually impair cognitive function and lead to AD.⁶⁰ There is evidence that AB oligomers are important neurotoxic forms, which are composed of two to 32 monomers.77-80 The neurotoxicity of A β oligomers is associated with the loss of synapses, a process that leads to hippocampal long-term potentiation decrease. This impairing effect of AB oligomers could underlie the cognitive impairment associated with AD.^{81,82} In the present study, we found that treatment of N2a/APP

cells with Coff or Caff plus Mel increased the extracellular levels of the monomeric form of A β 40/42 but decreased the extracellular level of A β oligomers, suggesting that the combination therapy suppressed A β oligomerization and thus increased the level of nontoxic monomers of A β peptides. Coff or Caff plus Mel combinations appeared to affect the equilibrium between A β monomers and oligomers, favoring the existence of A β monomers.

Intervention in the A β aggregation process has been considered as a practical approach to stop or slow the progression of AD. It has been demonstrated that Mel directly interacts with $A\beta$, and prevent its aggregation and inhibits the progressive formation β sheet d/or amyloid fibrils.^{83,84} Mel may accelerate the prversion of β sheets into random coils by discripting the imideal carboxylate salt bridges, which prevent AP forillogenesis and aggregation. It therefore blocks the secondary β sheet conformation. Moreover, Verlacilitates the clearance of A β peptides via creasing proteolytic degradation. On the other e cognitive impairment and improve memory function, AD and in other chronic neurodegenerative disorders, hugh the gulatory effect on mitochondrial function and Jaress.85 oxida

Previous studies on Coff, Caff, and Mel have shown beneficial effects in AD.^{86,87} However, there was no report on the combined use of Coff/Caff with Mel with chronological considerations. In our study, we treated A2a/APP cells with Coff/Caff in the day, followed with Mel in the night, which is consistent with rhythm of Mel secretion in human pineal gland. We therefore speculated that N2a/APP cells may have their own circadian rhythms, leading to different effects on cells treated with the same drug at the same concentration with different chronological regimens. To test this speculation, we treated N2a/APP cells with three different chronological regimens and found that the antiamyloidogenic effects of the Coff/Caff plus Mel was regimen-dependent, suggesting the importance of chronotherapy in AD treatment. A most remarkable and synergistic/additive effect on reduced extracellular Aβ40/42 level was observed in N2a/APP cells treated with regimen 1, where cells were treated with Caff/ Coff in day time, followed by Mel in night time, whereas this effect was smaller or disappeared when regimens 2 and 3 were used. These findings support the pathophysiological and therapeutic implications of circadian rhythms in AD. Previous studies have shown that Caff/Coff administration in day time benefited AD or dementia in mice or humans.⁸⁸⁻⁹⁰ It has also been shown that there is a circadian clock in N2a cells

267


and that treatments were only effective at specific circadian times.⁹¹ Abnormal and disturbed circadian rhythms are common in AD.^{30,46} Chronotherapeutic approaches aimed at bolstering weakened circadian rhythms in AD produce beneficial outcomes. A double-blind study of Mel in AD patients revealed improvements in cognition as well as decreasing nocturnal activity and increased nocturnal sleep.⁹² Further studies are needed to optimize the chronotherapy for AD using Coff/Caff and Mel.

Oxidative stress and impaired energy metabolism play an important role in the pathogenesis of AD.^{1,21,58,59} Cerebral tissues are particularly vulnerable to oxidative damage, due to its high oxygen consumption, low content of antioxidants, and high content of polyunsaturated fatty acids of neuronal membranes. AB itself and phosphorylated Tau cause oxidative damage to neurons.^{1,21,58,59} Mitochondrial dysfunction in AD could cause an increased generation of free radicals, and damage major cellular macromolecules, including DNA, proteins, and lipids. Dysregulation of Nrf2 plays a role in the development and pathogenesis of AD, and Nrf2 can attenuate Aβ-induced neurotoxicity and Tau phosphorylation.^{93–95} The neuroprotective and antiamyloidogenic activities of Coff, Caff, and Mel may be attributed to their antioxidative effects through the involvement of Nrf2 signaling pathway. Preous studies showed that Coff activated the Nrf2-mediate signaling pathway to exert its neuroprotective effect % Nrf2 is a nuclear transcription factor, playing a pive al role the regulation of oxidative stress by modulating the trans of antioxidant response elements.⁶⁸ The fect of 1 on Nrf2 luce oxida. activation indicates that Coff may stress through Nrf2-mediated signaling pathways. In addition, it has been reported that Mely ssesses a stron antioxidative effect.^{97,98} In the present, ady, we found that the combination of Coff/Caff plus Min remainen 1 significantly reduced the oxidative stre in N2. PP cell contributing to the iamyle in the effect. neuroprotectiv and a

It has been report 4 that inhibition of GSK3 can exhibit profound neurometerive effects, which have been proposed as promising and practical therapeutic targets for the treatment of AD.⁴⁸ GSK3 is regarded as a critical molecular link between senile plaques and neurofibrillary tangles. It can trigger the hyperphosphorylation of Tau, resulting in an exaggerated progressive condition of AD. Moreover, GSK3 can be inhibited by Akt in the Akt/GSK3 β /Tau pathway.⁹⁹ It has been shown that the regulatory effect of Mel on the Akt/ GSK3 β /Tau pathway is, at least in part, responsible for is beneficial effect.¹⁰⁰ Wang et al¹⁰¹ showed the consensus change in the Akt/Gsk3 β /Tau pathway in N2a cells. In agreement with the previous studies, our findings showed that phosphorylation levels of Akt, GSK3B, and Tau were decreased in N2a/ APP cells treated with the combination of Coff/Caff plus Mel. Notably, our studies provided evidence for the stronger effect of the combination of Caff in day time, followed by Mel in night time on inhibiting Tau hyperphosphorylation. Moreover, the combinations of Coff/Caff plus Mel negatively regulated Wnt/β-catenin signaling, which may contribute to the attenuation in the Akt/GSK3 β /Tau signaling in N2a/APP cells. Intriguingly, the combination of Coff/Caff plus Mel showed a promoting effect on the phoening dation of PI3K and Erk1/2 in N2a/APP cells. PI3K and Erk1/2 lay a critical role in the regulation of cell greath, cell mightion, cell survival, and cell death. All reguling effers of Coff/ Caff plus Mel on above portant signal, portant contribute to proprolife, ive, proprotective, and antiamyloidogenic activities in N2. PP cell

Inflammation and dysregul utophagy have a causal role in the pathogenetic of AD.¹⁰²⁻¹⁰⁵ However, our data did not surplue the concept of at Coff/Caff plus Mel produced hyloidogenic effect through modulation of these anti rocesses in 2a/APP cells. In other studies, Mel has two been own to be ve potent anti-inflammatory effects, via cytokine and nitric oxide production.^{106–108} uppressi Ca has a potent modulating effect on inflammation, rough adenosine receptor and other pathways.^{109,110} Both aff and Mel are potent inducers of autophagy in different nimal and disease models.^{63,111,112} Therefore, further studies are needed to explore the effects and the underlying mechanisms of Coff, Caff, and Mel on inflammation and autophagy.

In summary, Coff and Caff chronologically enhanced the antiamyloidogenic activity of Mel through suppression of Aβ oligomerization and modulation of the Akt/GSK3β/Tau pathway in N2a/APP cells (Figure 17). We have observed that the antiamyloidogenic effects of Coff/Caff plus Mel were more potent than were Coff, Caff, or Mel alone. Since Caff is mainly metabolized to paraxanthine, theobromine, and theophylline, and Mel is principally metabolized to 6-hydroxymelatonin, which is further conjugated with sulfate, these metabolites may contribute to the antiamyloidogenic action. Further studies are warranted to dissect the role of adenosine and melatonin receptors and other molecules for the neuroprotective and antiamyloidogenic activities of Coff or Caff plus Mel. These data will provide strong rationales for the Phase I trials on the combination of Coff or Caff, plus Mel in AD patients, when chronotherapy is taken into consideration.



olus Me Figure 17 Proposed mechanisms for the neuroprotective effects of Coff/C Notes: The combination of Coff/Caff plus Mel promotes the phosphorylati $_{\rm J}$ K and ErK1/2 and suppresses the phosphorylation of GSK3 β , Akt, and Tau in N2a/ of with i ction in the expression level of Wnt3lpha and Nrf2 and intracellular ROS level. At last, the APP cells. Moreover, the combinations repress Wnt and RQ ers, whic combinations decreased the extracellular level of A β olige re neur affeine; C melatonin; N2a, Neuro-2a; ROS, reactive oxygen species; GSK3 β , glycogen synthase Abbreviations: APP, amyloid precursor protein; Ca coffee; M kinase-3 β ; A β , amyloid- β .

Acknowledgmen

The authors appreciate the support ham the College of Pharmacy and More an College of Medicine, University of South Florida, Tan, FLOSA.

Disclorare

The autors represented on conflicts of interest in this work.

References

- 1. Ballard C, Gaberr S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer's disease. *Lancet*. 2011;377(9770):1019–1031.
- Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med. 2010; 362(4):329–344.
- Gilbert T, Herbst M. Alzheimer's disease: charting the crossroads between neurology and psychology. J Neurol Neurosurg Psychiatry. 2014;85(2):133–134.
- Reitz C, Mayeux R. Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. *Biochem Pharmacol*. 2014;88(4): 640–651.
- Ferri CP, Prince M, Brayne C, et al; Alzheimer's Disease International. Global prevalence of dementia: a Delphi consensus study. *Lancet*. 2005; 366(9503):2112–2117.

- Fargo K, Bleiler L. Alzheimer's Association report. *Alzheimers Dement*. 2014;10(2):e47–e92.
- Chan KY, Wang W, Wu JJ, et al; Global Health Epidemiology Reference Group (GHERG). Epidemiology of Alzheimer's disease and other forms of dementia in China, 1990–2010: a systematic review and analysis. *Lancet*. 2013;381(9882):2016–2023.
- Weuve J, Hebert LE, Scherr PA, Evans DA. Deaths in the United States among persons with Alzheimer's disease (2010–2050). *Alzheimers Dement*. 2014;10(2):e40–e46.
- Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet*. 2012;380(9859):2095–2128.
- Gulland A. Number of people with dementia will reach 65.7 million by 2030, says report. *BMJ*. 2012;344:e2604.
- Wimo A, Jönsson L, Bond J, Prince M, Winblad B; Alzheimer Disease International. The worldwide economic impact of dementia 2010. *Alzheimers Dement*. 2013;9(1):1–11.e3.
- Wimo A, Winblad B, Jönsson L. The worldwide societal costs of dementia: Estimates for 2009. *Alzheimers Dement*. 2010;6(2): 98–103.
- Ittner LM, Götz J. Amyloid-β and Tau a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci. 2011;12(2):65–72.
- Haass C, Mandelkow E. Fyn-Tau-amyloid: a toxic triad. Cell. 2010; 142(3):356–358.

- Huang Y, Mucke L. Alzheimer mechanisms and therapeutic strategies. *Cell*. 2012;148(6):1204–1222.
- Selkoe DJ. SnapShot: pathobiology of Alzheimer's disease. Cell. 2013; 154(2):468–468.e1.
- Bloom GS. Amyloid-β and Tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol. 2014;71(4):505–508.
- Kandalepas PC, Vassar R. Identification and biology of β-secretase. J Neurochem. 2012;120 Suppl 1:S55–S61.
- Wang H, Li R, Shen Y. β-Secretase: its biology as a therapeutic target in diseases. *Trends Pharmacol Sci.* 2013;34(4):215–225.
- Yan R, Vassar R. Targeting the β secretase BACE1 for Alzheimer's disease therapy. *Lancet Neurol*. 2014;13(3):319–329.
- 21. Karran E, Hardy J. Antiamyloid therapy for Alzheimer's disease are we on the right road? *N Engl J Med*. 2014;370(4):377–378.
- Aguzzi A, Gitler AD. A template for new drugs against Alzheimer's disease. *Cell.* 2013;154(6):1182–1184.
- Gandy S, DeKosky ST. Toward the treatment and prevention of Alzheimer's disease: rational strategies and recent progress. *Annu Rev Med.* 2013;64:367–383.
- Butt MS, Sultan MT. Coffee and its consumption: benefits and risks. Crit Rev Food Sci Nutr. 2011;51(4):363–373.
- Biessels GJ. Caffeine, diabetes, cognition, and dementia. J Alzheimers Dis. 2010;20 Suppl 1:S143–S150.
- 26. Barrenetxe J, Delagrange P, Martinez JA. Physiological and metabolic functions of melatonin. *J Physiol Biochem*. 2004;60(1):61–72.
- Cipolla-Neto J, Amaral FG, Afeche SC, Tan DX, Reiter RJ. Melatonin, energy metabolism, and obesity: a review. *J Pineal Res.* 2014;56(4): 371–381.
- Dubocovich ML, Markowska M. Functional MT1 and MT2 melatonin receptors in mammals. *Endocrine*. 2005;27(2):101–110.
- Liu RY, Zhou JN, van Heerikhuize J, Hofman MA, Swaab DF. Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer's disease, and apolipoprotein E-epsilon genotype. J Clin Endocrinol Metab. 1999;84(1):323–327.
- Naismith SL, Hickie IB, Terpening Z, et al. Circadian misalignmen and sleep disruption in mild cognitive impairment. *J Alzkeiners Dis.* 2014;38(4):857–866.
- Carman AJ, Dacks PA, Lane RF, Shineman DW, Mait HM. Jurrent evidence for the use of coffee and caffeine to preve age-relation of tive decline and Alzheimer's disease. *J Nutr V alth Age 9*, 914;18(4): 383–392.
- 32. Arendash GW, Cao C. Caffeine and the state as therapeur against Alzheimer's disease. *J Alzheimers* 4.8, 2010, Suppl 1:S11, S126.
- 33. Arendash GW, Schleif W, Rezh-Zadeh K, etc. Caffeine protects Alzheimer's mice against constitive impairment of reduces brain beta-amyloid production *conscience*, 2006;142(4):941–952.
- 34. Canas PM, Porciúncula S, Cunhon M, et al. Adenosine A2A receptor blockade prevents synap a construction and more ory dysfunction caused by beta-amyloid of bles via \$8 mitor activated protein kinase pathway. J Neurosci. 2019;29(4):0470–14751.
- Dragicevice, Bradsberg PC, Mamenz M, et al. Long-term electromagnetic 1 el trere annuelle sobrain mitochondrial function of both Alzheim en ansgenic mice and normal mice: a mechanism for electromagnetic real-induced cognitive benefit? *Neuroscience*. 2011; 185:135–149.
- Cao C, Loewenstein DA, Lin X, et al. High Blood caffeine levels in MCI linked to lack of progression to dementia. *J Alzheimers Dis.* 2012;30(3): 559–572.
- Cao C, Wang L, Lin X, et al. Caffeine synergizes with another coffee component to increase plasma GCSF: linkage to cognitive benefits in Alzheimer's mice. *J Alzheimers Dis.* 2011;25(2):323–335.
- He H, Dong W, Huang F. Anti-amyloidogenic and anti-apoptotic role of melatonin in Alzheimer disease. *Curr Neuropharmacol*. 2010;8(3): 211–217.
- Lahiri DK. Melatonin affects the metabolism of the beta-amyloid precursor protein in different cell types. *J Pineal Res.* 1999;26(3): 137–146.

- Dibner C, Schibler U, Albrecht U. The mammalian circadian timing system: organization and coordination of central and peripheral clocks. *Annu Rev Physiol.* 2010;72:517–549.
- 41. Levi F, Schibler U. Circadian rhythms: mechanisms and therapeutic implications. *Annu Rev Pharmacol Toxicol*. 2007;47:593–628.
- 42. Reppert SM, Weaver DR. Coordination of circadian timing in mammals. *Nature*. 2002;418(6901):935–941.
- Scheiermann C, Kunisaki Y, Frenette PS. Circadian control of the immune system. *Nat Rev Immunol*. 2013;13(3):190–198.
- Hermida RC, Ayala DE, Smolensky MH, et al. Chronotherapy improves blood pressure control and reduces vascular risk in CKD. *Nat Rev Nephrol.* 2013;9(6):358–368.
- Sahar S, Sassone-Corsi P. Metabolism and cancer: the circadian clock connection. *Nat Rev Cancer*. 2009;9(12):886–896.
- Coogan AN, Schutová B, Husung S, et al. The sircadian system in Alzheimer's disease: disturbances, mechanisms, and opportunities. *Biol Psychiatry*. 2013;74(5):333–339
- Kaur G, Phillips C, Wong K, Saini B. Thong is important amedication administration: a timely review ochronic grapy research. Int J Clin Pharm. 2013;35(3):344–358
- Llorens-Martín M, Jurader Hernándo F, Avin To SK-3β, a pivotal kinase in Alzheimer disco From fol Neurosci. 2014;7:46.
- Ghavami S, Shojan S, Yegan B, et al. Acophagy and apoptosis dysfunction in proceeding disorder *prog Neurobiol*. 2014;112: 24–49.
- Tan CC, Y. J, Tan S, Jiang T, Zhe XC, Tan L. Autophagy in aging and neurodegenerative reseases: implications for pathogenesis and the provide the second seco
- 51. Yong ZX, Sun J, Howell CE, et al. Prediction of the likelihood of drug teractions with thase inhibitors based on in vitro and computational dies. *Fundam in Pharmacol.* 2014;28(5):551–582.
- 52. LL, H, Mo SL, HC, et al. Regulation of human pregnane X receptor and https://www.acceptor
- 53 no Liu WF, Chen Y, et al. Ligand- and protein-based modeling studies of the inhibitors of human cytochrome P450 2D6 and a virtual screening for potential inhibitors from the Chinese herbal medicine, Scutellaria baicalensis (Huangqin, Baikal Skullcap). *Comb Chem High Throughput Screen*. 2012;15(1):36–80.
- Mo SL, Liu WF, Li CG, et al. Pharmacophore, QSAR, and binding mode studies of substrates of human cytochrome P450 2D6 (CYP2D6) using molecular docking and virtual mutations and an application to Chinese herbal medicine screening. *Curr Pharm Biotechnol*. 2012;13(9): 1640–1704.
- 55. Yang LP, Zhou ZW, Chen XW, et al. Computational and in vitro studies on the inhibitory effects of herbal compounds on human cytochrome P450 1A2. *Xenobiotica*. 2012;42(3):238–255.
- Ma QL, Lim GP, Harris-White ME, et al. Antibodies against betaamyloid reduce Abeta oligomers, glycogen synthase kinase-3beta activation and Tau phosphorylation in vivo and in vitro. *J Neurosci Res.* 2006;83(3):374–384.
- 57. Kayed R, Head E, Sarsoza F, et al. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. *Mol Neurodegener*. 2007;2:18.
- Saido TC. Metabolism of amyloid β peptide and pathogenesis of Alzheimer's disease. *Proc Jpn Acad Ser B Phys Biol Sci.* 2013;89(7): 321–339.
- Mawuenyega KG, Sigurdson W, Ovod V, et al. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. *Science*. 2010;330(6012):1774.
- Taylor RC, Cullen SP, Martin SJ. Apoptosis: controlled demolition at the cellular level. *Nat Rev Mol Cell Biol.* 2008;9(3):231–241.
- Maes H, Rubio N, Garg AD, Agostinis P. Autophagy: shaping the tumor microenvironment and therapeutic response. *Trends Mol Med.* 2013; 19(7):428–446.
- Klionsky DJ, Emr SD. Autophagy as a regulated pathway of cellular degradation. *Science*. 2000;290(5497):1717–1721.

- Chen J, Wang L, Wu C, et al. Melatonin-enhanced autophagy protects against neural apoptosis via a mitochondrial pathway in early brain injury following a subarachnoid hemorrhage. *J Pineal Res.* 2014;56(1): 12–19.
- 64. Swomley AM, Förster S, Keeney JT, et al. Abeta, oxidative stress in Alzheimer disease: evidence based on proteomics studies. *Biochim Biophys Acta*. 2014;1842(8):1248–1257.
- Wang X, Wang W, Li L, Perry G, Lee HG, Zhu X. Oxidative stress and mitochondrial dysfunction in Alzheimer's disease. *Biochim Biophys Acta*. 2014;1842(8):1240–1247.
- Aliev G, Obrenovich ME, Reddy VP, et al. Antioxidant Therapy in Alzheimer's Disease: Theory and Practice. *Mini Rev Med Chem.* 2008;8(13):1395–1406.
- Suzuki T, Motohashi H, Yamamoto M. Toward clinical application of the Keap1-Nrf2 pathway. *Trends Pharmacol Sci.* 2013;34(6):340–346.
- Ma Q. Role of nrf2 in oxidative stress and toxicity. Annu Rev Pharmacol Toxicol. 2013;53:401–426.
- Purro SA, Galli S, Salinas PC. Dysfunction of Wnt signaling and synaptic disassembly in neurodegenerative diseases. *J Mol Cell Biol.* 2014;6(1):75–80.
- Hernandez F, Lucas JJ, Avila J. GSK3 and Tau: two convergence points in Alzheimer's disease. J Alzheimers Dis. 2013;33 Suppl 1: S141–S144.
- Eskelinen MH, Ngandu T, Tuomilehto J, Soininen H, Kivipelto M. Midlife coffee and tea drinking and the risk of late-life dementia: a population-based CAIDE study. *J Alzheimers Dis.* 2009;16(1): 85–91.
- Santos C, Costa J, Santos J, Vaz-Carneiro A, Lunet N. Caffeine intake and dementia: systematic review and meta-analysis. *J Alzheimers Dis.* 2010;20 Suppl 1:S187–S204.
- Hsiao K, Chapman P, Nilsen S, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. *Science*. 1996;274(5284):99–102.
- 74. Shimizu H, Tosaki A, Kaneko K, Hisano T, Sakurai T, Nuce N, Crystal structure of an active form of BACE1, an enzyme resp usible for amyloid beta protein production. *Mol Cell Biol.* 2008;22 (1): 3663–3671.
- Hong L, Tang J. Flap position of free memapsize (be asecretal a model for flap opening in aspartic protease analysis. *J. chemistr.* 2004;43(16):4689–4695.
- 76. Yuan J, Venkatraman S, Zheng Y, J. Kees, Port, Dillard EW, Singh SB. Structure-based design on p-site APP maying enzyme 1 (BACE1) inhibitors for the treatent of Alzheimer ensease. *J Med Chem.* 2013; 56(11):4156–418
- Wilcox KC, Lacor PN, Pitte Klein WL. Appligomer-induced synapse degeneration in Alzheir es disease. *Cell Mon Eurobiol*. 2011;31(6): 939–948.
- Benilova I, Karra E, De Stroper B. The toxic Aβ oligomer and Alzheimer's disease: a preparor in need Colothes. *Nat Neurosci*. 2012; 15(3):349-2
- Citron Ma Alzhei, an's disease set regies for disease modification. Nat Rev 1 ag Discov <u>4010</u>;9(5):35, <u>4398</u>.
- Klein, J., Sympton Loid-β oligomers: a molecular basis for the cause, discussis, and treatment of Alzheimer's disease? *J Alzheimers Dis*. 2013;5: http://dxia.org/10.1113/10.1113
- Barghorn S, Namurich V, Striebinger A, et al. Globular amyloid betapeptide oligomer – a homogenous and stable neuropathological protein in Alzheimer's disease. *J Neurochem*. 2005;95(3):834–847.
- Gong Y, Chang L, Viola KL, et al. Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. *Proc Natl Acad Sci U S A*. 2003; 100(18):10417–10422.
- Poeggeler B, Miravalle L, Zagorski MG, et al. Melatonin reverses the profibrillogenic activity of apolipoprotein E4 on the Alzheimer amyloid Abeta peptide. *Biochemistry*. 2001;40(49):14995–15001.
- Masilamoni JG, Jesudason EP, Dhandayuthapani S, et al. The neuroprotective role of melatonin against amyloid beta peptide injected mice. *Free Radic Res.* 2008;42(7):661–673.

- Cunha RA, Agostinho PM. Chronic caffeine consumption prevents memory disturbance in different animal models of memory decline. *J Alzheimers Dis.* 2010;20 Suppl 1:S95–S116.
- Zhang YC, Wang ZF, Wang Q, Wang YP, Wang JZ. Melatonin attenuates beta-amyloid-induced inhibition of neurofilament expression. *Acta Pharmacol Sin*. 2004;25(4):447–451.
- Wang XC, Zhang YC, Chatterjie N, Grundke-Iqbal I, Iqbal K, Wang JZ. Effect of melatonin and melatonylvalpromide on betaamyloid and neurofilaments in N2a cells. *Neurochem Res.* 2008; 33(6):1138–1144.
- Flaten V, Laurent C, Coelho JE, et al. From epidemiology to pathophysiology: what about caffeine in Alzheimer's disease? *Biochem Soc Trans.* 2014;42(2):587–592.
- Laurent C, Eddarkaoui S, Derisbourg M, et al. Beneficial effects of caffeine in a transgenic model of Abbeimer's disease-like Tau pathology. *Neurobiol Aging*. 2014 (9):200 2090.
- 90. Jiang T, Yu JT, Tian Y, Tarrez, Epidemiologi and etiology of Alzheimer's disease: from genuic to non-genuic factors. *Curr Alzheimer Res.* 2013;10(2):852–86
- 91. Repouskou A, Sourling & TG, Sekeri-Loryas M, Prombona A. The circadian expression (c-MYC) nodulate the nehistone deacetylase inhibitor trichosta (A) in structure neuroblastoma cells. *Chronobiol* 10, 2010, 2017, 722–741
- 92. Asayaman, Yamadera Loto T, Schaki H, Kudo Y, Endo S. Double blind may Emelatonin en upper the sleep-wake rhythm, cognitive and on-cognitive functions in Alzheimer type dementia. *J Nippon Med Sch.* 2003; 10:334–341.
- Kan Jinen K, Malmur Jyrkkänen HK, et al. Nuclear factor erythroid
 2-related factor 2 protects against beta amyloid. *Mol Cell Neurosci*.
 2008;39(3-02-313.
- 4. Jo C, Gunchnir S, Pritchard S, Jin YN, Rahman I, Johnson GV. Nrf2 reduces law is of phosphorylated Tau protein by inducing autophagy rotein NDP52. *Nat Commun.* 2014;5:3496.
- Kärkkäinen V, Pomeshchik Y, Savchenko E, et al. Nrf2 regulates urogenesis and protects neural progenitor cells against Aβ toxicity. *Stem Cells*. 2014;32(7):1904–1916.
- Trinh K, Andrews L, Krause J, et al. Decaffeinated coffee and nicotine-free tobacco provide neuroprotection in Drosophila models of Parkinson's disease through an NRF2-dependent mechanism. *J Neurosci*. 2010;30(16):5525–5532.
- Singh M, Jadhav HR. Melatonin: functions and ligands. Drug Discov Today. 2014;19(9):1410–1418.
- Vielma JR, Bonilla E, Chacín-Bonilla L, Mora M, Medina-Leendertz S, Bravo Y. Effects of melatonin on oxidative stress, and resistance to bacterial, parasitic, and viral infections: a review. *Acta Trop.* 2014;137: 31–38.
- 99. Zhang X, Shi M, Ye R, et al. Ginsenoside Rd attenuates Tau protein phosphorylation via the PI3K/AKT/GSK-3β pathway after transient forebrain ischemia. *Neurochem Res.* 2014;39(7):1363–1373.
- Lin L, Huang QX, Yang SS, Chu J, Wang JZ, Tian Q. Melatonin in Alzheimer's disease. *Int J Mol Sci.* 2013;14(7):14575–14593.
- 101. Wang Y, Liu W, He X, Zhou F. Parkinson's disease-associated DJ-1 mutations increase abnormal phosphorylation of Tau protein through Akt/GSK-3β pathways. *J Mol Neurosci*. 2013;51(3):911–918.
- Lynch MA. The impact of neuroimmune changes on development of amyloid pathology; relevance to Alzheimer's disease. *Immunology*. 2014;141(3):292–301.
- 103. Ułamek-Kozioł M, Furmaga-Jabłońska W, Januszewski S, et al. Neuronal autophagy: self-eating or self-cannibalism in Alzheimer's disease. *Neurochem Res.* 2013;38(9):1769–1773.
- Nixon RA. The role of autophagy in neurodegenerative disease. *Nat* Med. 2013;19(8):983–997.
- Orr ME, Oddo S. Autophagic/lysosomal dysfunction in Alzheimer's disease. *Alzheimers Res Ther.* 2013;5(5):53.
- 106. Vilar A, de Lemos L, Patraca I, et al. Melatonin suppresses nitric oxide production in glial cultures by pro-inflammatory cytokines through p38 MAPK inhibition. *Free Radic Res.* 2014;48(2):119–128.

- 107. Aparicio-Soto M, Alarcón-de-la-Lastra C, Cárdeno A, Sánchez-Fidalgo S, Sanchez-Hidalgo M. Melatonin modulates microsomal PGE synthase 1 and NF-E2-related factor-2-regulated antioxidant enzyme expression in LPS-induced murine peritoneal macrophages. *Br J Pharmacol.* 2014;171(1):134–144.
- Alamili M, Bendtzen K, Lykkesfeldt J, Rosenberg J, Gögenur I. Melatonin suppresses markers of inflammation and oxidative damage in a human daytime endotoxemia model. *J Crit Care*. 2014;29(1):184. e9–e184.e13.
- Weichelt U, Cay R, Schmitz T, et al. Prevention of hyperoxia-mediated pulmonary inflammation in neonatal rats by caffeine. *Eur Respir J*. 2013;41(4):966–973.
- 110. Gołembiowska K, Wardas J, Noworyta-Sokołowska K, Kamiska K, Górska A. Effects of adenosine receptor antagonists on the in vivo LPS-induced inflammation model of Parkinson's disease. *Neurotox Res.* 2013;24(1):29–40.
- Saiki S, Sasazawa Y, Imamichi Y, et al. Caffeine induces apoptosis by enhancement of autophagy via PI3K/Akt/mTOR/p70S6K inhibition. *Autophagy*. 2011;7(2):176–187.
- 112. Sinha RA, Farah BL, Singh BK, et al. Caffeine stimulates hepatic lipid metabolism by the autophagy-lysosomal pathway in mice. *Hepatology*. 2014;59(4):1366–1380.

 $\textbf{Submit your manuscript here:} \ \texttt{http://www.dovepress.com/drug-design-development-and-therapy-journal}$

Drug Design, Development and Therapy

Publish your work in this journal

Drug Design, Development and Therapy is an international, peer-

reviewed open-access journal that spans the spectrum of drug design

and development through to clinical applications. Clinical outcomes,

patient safety, and programs for the development and effective, safe,

and sustained use of medicines are a feature of the journal, which

has also been accepted for indexing on PubMed Central. The manu-

script management system is completely online and includes a very

quick and fair peer-review system, which is all easy to use. Visit

http://www.dovepress.com/testimonials.php to read real quotes from

published authors.

